ArticleRadiology2025
External Testing of a Deep Learning Model for Lung Cancer Risk from Low-Dose Chest CT.
Article in Radiology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Recent advances in artificial intelligence across interventional pulmonology: a narrative review.Journal of thoracic disease · 2026Review
- [Expert Consensus on Precision Management of Pulmonary Nodules (2026 Version)].Zhongguo fei ai za zhi = Chinese journal of lung cancer · 2026Article
- Development and validation of an LDCT-based deep learning radiomics nomogram for predicting postoperative recurrence of stage Ia lung adenocarcinoma.Frontiers in oncology · 2025Article
Corrections and comments
- Commented on by
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background Sybil, an open-source deep learning model that uses low-dose CT (LDCT) for lung cancer prediction, requires rigorous external testing to confirm generalizability. Additionally, its utility in identifying individuals with high risk who never smoked or have light smoking histories remains unanswered. Purpose To externally test Sybil for identifying individuals with high risk for lung cancer within an Asian health checkup cohort. Materials and Methods This retrospective study analyzed LDCT scans from a single medical checkup facility in a study sample of individuals aged 50-80 years, collected between January 2004 and December 2021, with at least one follow-up scan. The predictive performance of the model for lung cancer risk over a 6-year period was assessed using the time-dependent area under the receiver operating characteristic curve (AUC). These evaluations were conducted in the overall study sample and within subgroups of patients with heavy (at least 20 pack-years) and never- or light smoking histories (ie, ever smoking [median, 2 pack-years]; ineligible for lung cancer screening per 2021 U.S. Preventive Services Task Force recommendations). Additionally, performance was evaluated according to the visibility of lung cancers on baseline LDCT scans. Results: Among 18 057 individuals (median age, 56 years [IQR, 52-61 years]; 11 267 male), 92 lung cancers were diagnosed (0.5%) within 6 years. Of these, 2848 had heavy smoking histories and 9943 had never- or light smoking histories, with 24 (0.8%) and 41 (0.4%) lung cancers, respectively. Sybil achieved AUCs of 0.91 for 1-year risk and 0.74 for 6-year risk. In the heavy-smoking subgroup, 1-year AUC was 0.94 (for visible lung cancers) and 6-year AUC was 0.70 (for future lung cancers). For the never- or light-smoking subgroup, Sybil had an AUC of 0.89 for visible lung cancers and 0.56 for future lung cancers. Conclusion: Sybil demonstrated excellent discriminative performance for visible lung cancers and acceptable performance for future lung cancers in Asian individuals with heavy smoking history but demonstrated poor performance for future lung cancers in a never- or light-smoking subgroup. © RSNA, 2025
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.